Prostate Specific Antigen, Total - Medicare Screening
Ordering Recommendation
Preferred initial screening test for prostate cancer in conjunction with digital rectal exam. May use to monitor patients for recurrence of cancer.
Submit With Order
Quantitative Electrochemiluminescent Immunoassay
Within 24 hours
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Serum separator tube or plasma separator tube. Also acceptable: Plain red, green (sodium or lithium heparin), lavender (EDTA), or pink (K2EDTA).  
Specimen Preparation
Transport 1 mL serum or plasma. (Min: 0.5 mL)  
Storage/Transport Temperature
Unacceptable Conditions
Hemolyzed specimens.  
Ambient: 8 hours; Refrigerated: 5 days; Frozen: 6 months  
Reference Interval
0.0-4.0 ng/mL
Interpretive Data
The Roche PSA electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma.
This test should be ordered for screening purposes for Medicare patients only.
CPT Code(s)
Component Test Code*Component Chart Name
0070234Prostate Spec Ag Total Screen
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • PSA
  • Screen for Prostate Specific Ag
  • sPSA